Overview

A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

Status:
Completed

Trial end date:
2016-03-21

Target enrollment:

Participant gender:

Summary

To characterize the pharmacokinetics of LCI699 following a single oral dose in adult subjects with various degrees of impaired renal function.

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals